|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2003; 41:8-14 © 2003 by the American College of Cardiology Foundation |
* Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière (AP-HP), Paris, France
Department of Biostatistics, Pitié-Salpêtrière Hospital, Paris, France
Hemostasis Laboratory, Pitié-Salpêtrière Hospital, Paris, France
Manuscript received April 17, 2002; revised manuscript received May 30, 2002, accepted August 29, 2002.
* Reprint requests and correspondence: Dr. Gilles Montalescot, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière (AP-HP), 47 boulevard de l’Hôpital, 75013 Paris, France.
gilles.montalescot{at}psl.ap-hop-paris.fr
OBJECTIVES: In the present study, we describe the characteristics and examine the anticoagulation levels and safety of subcutaneous enoxaparin in unstable angina (UA)/non–ST-segment elevation myocardial infarction (NSTEMI) patients who would not have been eligible in the Efficacy Safety Subcutaneous Enoxaparin in Non–Q-wave Coronary Events (ESSENCE) and Thrombolysis In Myocardial Infarction (TIMI)-11B trials.
BACKGROUND: It is not known whether the benefit shown with enoxaparin in the selected population of pivotal trials can be extended to the real world.
METHODS: In our center, all patients with UA/NSTEMI are anticoagulated with subcutaneous enoxaparin adjusted to creatinine clearance. Among 515 consecutive patients, we identified 174 who would not have been eligible for ESSENCE or TIMI-11B ("EP" group for excluded patients). We evaluated cardiovascular death or non-fatal myocardial infarction (MI), as well as major and minor bleeding events, at 30 days in the EP group and in patients without any of the exclusion criteria ("NEP" group for non-excluded patients).
RESULTS: This EP group was older, had a higher female/male ratio, and more frequently had a history of MI or a diagnosis of non-Q MI on admission than the NEP group. The distribution of the anti-Xa activity was similar in both groups. The bleeding rates (major and minor) at 30 days were similar in the EP and NEP groups (2.3% vs. 2.9%, respectively, p = NS). On multivariate analysis, the use of glycoprotein IIb/IIIa inhibitors and the presence of hypertension were the only independent predictors of bleeding found in the whole population. Compared with the NEP group, the EP group had a fourfold increased rate of death or MI at 30 days (15.5% vs. 4.1%, p < 0.01). On multivariate analysis, the independent predictors of death or MI at 30 days were NSTEMI on admission, creatinine clearance, and heart failure.
CONCLUSIONS: Patients who do not fit the enrollment criteria of ESSENCE/TIMI-11B have higher risk baseline characteristics for both bleeding and ischemic events. In these patients, enoxaparin with dose adjustment to creatinine clearance provides adequate anti-Xa levels and no excess of bleeding.
| ||||||||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  N. M. A. LaPointe, A. Y. Chen, K. P. Alexander, M. T. Roe, C. V. Pollack Jr, B. L. Lytle, M. E. Ohman, B. W. Gibler, and E. D. Peterson Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Arch Intern Med, July 23, 2007; 167(14): 1539 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Collet, R. Dumaine, and G. Montalescot Antithrombin treatment in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A11 - A24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lim, F. Dentali, J. W. Eikelboom, and M. A. Crowther Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency Ann Intern Med, May 2, 2006; 144(9): 673 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Alexander, A. Y. Chen, M. T. Roe, L. K. Newby, C. M. Gibson, N. M. Allen-LaPointe, C. Pollack, W. B. Gibler, E. M. Ohman, E. D. Peterson, et al. Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, December 28, 2005; 294(24): 3108 - 3116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Collet, G. Montalescot, G. Agnelli, F. Van de Werf, E. P. Gurfinkel, J. Lopez-Sendon, C. V. Laufenberg, M. Klutman, N. Gowda, D. Gulba, et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events Eur. Heart J., November 1, 2005; 26(21): 2285 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Pineo and R. D. Hull Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism in the Elderly Clinical and Applied Thrombosis/Hemostasis, January 1, 2005; 11(1): 15 - 23. [Abstract] [PDF]
|
|
|
|
|
|
C. M. Gibson, R. L. Dumaine, E. V. Gelfand, S. A. Murphy, D. A. Morrow, S. D. Wiviott, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials Eur. Heart J., November 2, 2004; 25(22): 1998 - 2005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Montalescot, J.P. Collet, M.L. Tanguy, A. Ankri, L. Payot, R. Dumaine, R. Choussat, F. Beygui, V. Gallois, and D. Thomas Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin Circulation, July 27, 2004; 110(4): 392 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Macie, L. Forbes, G. A. Foster, and J. D. Douketis Dosing Practices and Risk Factors for Bleeding in Patients Receiving Enoxaparin for the Treatment of an Acute Coronary Syndrome Chest, May 1, 2004; 125(5): 1616 - 1621. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
